Highlights:
-One-year IMPROVE data suggest benefit of EVAR in ruptured aneurysms
-New Eluvia drug-eluting stent shows 94.4% primary patency rate at nine months
-Michael Dake: Arch branded device
-Andrew Holden: Bioresorbable stents
-Profile: Janet Powell
[pdfviewer width=”100%” height=”940px” beta=”true”]https://vascularnews.com/wp-content/uploads/sites/7/2016/02/66-Vascular-News-USA.pdf[/pdfviewer]
